{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:38:20Z","timestamp":1792683500828,"version":"4.5.0"},"reference-count":0,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Medical Sciences"],"abstract":"<jats:p>Background\/aim: To determine the effects of an A2A receptor agonist regadenoson, an A2A receptor antagonist istradefylline, and istradefylline nanosuspension on ovarian ischemia\/reperfusion (I\/R) injury in rats.\nMaterials and methods:  A total of 80 female rats were divided into 10 groups: sham, ovarian I\/R, blank nanosuspension + ovarian I\/R, regadenoson (3 \u03bcg\/kg) + ovarian I\/R, regadenoson (30 \u03bcg\/kg) + ovarian I\/R, istradefylline (0.3 mg\/kg) + ovarian I\/R, istradefylline (3 mg\/kg) + ovarian I\/R, istradefylline-loaded nanosuspension (3 mg\/kg) + ovarian I\/R, istradefylline (3 mg\/kg) + regadenoson (30 \u03bcg\/kg) + ovarian I\/R, and istradefylline-loaded nanosuspension (3 mg\/kg) + regadenoson (30 \u03bcg\/kg) + ovarian I\/R. ELISA, chemiluminescence, and spectrophotometric analyses were performed on blood and ovarian tissue samples. Histopathological changes were analyzed using hematoxylin and eosin staining, and a scoring system was applied to assess ovarian tissue damage.\nResults: Serum malondialdehyde levels were augmented in the I\/R and blank nanosuspension + I\/R groups. Although tissue superoxide dismutase levels were decreased with I\/R, these levels were increased with regadenoson (3 \u03bcg\/kg), istradefylline (0.3\u20133 mg\/kg), and istradefylline nanosuspension (3 mg\/kg). While there was augmentation in the serum and tissue 3-nitrotyrosine levels in the I\/R group, a marked decrease was identified with regadenoson (30 \u03bcg\/kg, p &lt; 0.05). Native thiol levels were decreased in the I\/R group, and this decrease was prevented by regadenoson. Serum disulfide levels were increased in the I\/R group, and this increase was suppressed by regadenoson.\nConclusion: These data showed that adenosine A2A receptors may contribute to the ovarian I\/R injury and regadenoson can produce protective effects.<\/jats:p>","DOI":"10.55730\/1300-0144.6170","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T02:32:50Z","timestamp":1771122770000},"page":"364-376","source":"Crossref","is-referenced-by-count":1,"title":["Contribution of adenosine A2A receptor agonist and antagonist on ovarian ischemia\/reperfusion injury in rats"],"prefix":"10.55730","volume":"56","author":[{"given":"AZAD","family":"MAMMADOV","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABDULLAH TUNCAY","family":"DEM\u0130RY\u00dcREK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AHMET","family":"SARACALO\u011eLU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAH\u0130T","family":"DEM\u0130RKIRAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130SMA\u0130L TUNCER","family":"DE\u011e\u0130M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6MER","family":"ERONAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eEN\u0130Z","family":"DEM\u0130RY\u00dcREK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2026,2,12]]},"container-title":["Turkish Journal of Medical Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:43:38Z","timestamp":1792680218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/medical\/vol56\/iss1\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.55730\/1300-0144.6170","relation":{},"ISSN":["1300-0144"],"issn-type":[{"value":"1300-0144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}